Insider Stock Sale by CEO
On September 25 2026, August J. Troendle, President and Chief Executive Officer of Medpace Holdings, Inc. (NASDAQ:MEDP), disposed of 154 shares of Medpace common stock at $620.60 per share. Three days later, on September 28 2026, he sold an additional 2,410 shares at a weighted‑average price of $620.07, with individual transaction prices ranging from $620.00 to $621.20. The combined proceeds from these two transactions total approximately $1.59 million. The sales were executed via a limit order placed during an open‑window period.
Following the disposals, Troendle directly retains 386,892 shares of Medpace common stock. He also indirectly benefits from 4,733,019 shares held through Medpace Investors, LLC, where he is the sole manager and controlling unit holder; he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
The market reacted positively, with Medpace’s share price rising to $669.20, near its 52‑week high of $684.52, and the stock being flagged as overvalued relative to its fair‑value estimate by InvestingPro.
Third‑Quarter 2026 Financial Performance
Medpace reported robust Q3 2026 results, delivering revenue of $716 million, marginally above the consensus estimate of $714.47 million and representing an 8.5% increase year‑over‑year. Adjusted earnings per share were $4.84, surpassing the forecast of $4.44. Net income grew 23.7% compared with the prior year, and the EBITDA margin expanded to 24.0% from 22.5% a year earlier, driven by lower reimbursable costs.
The company recorded a record‑high volume of net new business awards, which expanded its backlog and underscored strong demand, particularly in the oncology segment, despite a slight decline in cardiometabolic demand. Management consequently raised its full‑year 2026 revenue and profit guidance. However, the firm postponed its 2027 guidance to February, citing uncertainties around future awards and potential cancellations.
Additional Context
The article was generated with AI assistance and reviewed by an editor, with the source attributed to Reuters.